Rupafin® (rupatadine) is an antihistamine predominantly with H1 receptor antagonist effect indicated in seasonal and chronic rhinoconjunctivitis and urticaria.
It is IRF's overall assessment that rupatadine's efficacy and adverse reactions are comparable to the existing non-sedating H1 receptor antagonists indicated in rhinoconjunctivitis and urticaria. Thus, the price should be the primary guide for the choice of treatment, and rupatadine ranks among the most expensive antihistamines at present.
Rupatadine was introduced in Denmark on 8 June 2015 and carries general reimbursement. Unlike certain other non-sedating antihistamines (cetirizine, loratadine, etc.), rupatadine is prescription-only (dispensing status B).